Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27917303 | 0.98 | KDM4E (0.57) | KDM4ERAB9ANPC1ALDH1A1NFKB1 | |
| SCHEMBL10840639 | 0.82 | KDM4E (0.41) | KDM4ERAB9ANPC1ALDH1A1NFKB1 | |
| SCHEMBL15452693 | 0.82 | PDK1 (0.48) | KDM4ERAB9ANPC1ALDH1A1NFKB1 | |
| SCHEMBL2570916 | 0.82 | ALDH1A1 (0.54) | KDM4ERAB9ANPC1ALDH1A1NFKB1 | |
| SCHEMBL18131023 | 0.80 | KDM4E (0.50) | KDM4ERAB9AALDH1A1SMN1; SMN2NAPRT | |
| SCHEMBL28052420 | 0.78 | KDM4E (0.45) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31086825 | 0.78 | KDM4E (0.45) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2569126 | 0.78 | KDM4E (0.47) | KDM4ERAB9ANPC1ALDH1A1NFKB1 | |
| SCHEMBL10840340 | 0.77 | KDM4E (0.45) | KDM4ERAB9ANPC1ALDH1A1NFKB1 | |
| SCHEMBL10458612 | 0.77 | KDM4E (0.55) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680116-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-07-19 | — | — | EP | claimed |
| EP-1663215-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1- RECEPTOR ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2006-06-07 | — | — | EP | claimed |
| US-20050101585-A1 | Use of selective CB1-antagonists in medical treatments | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-12 | — | — | US | claimed |
| WO-2005039579-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | claimed |
| WO-2005020992-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-03-10 | — | — | WO | claimed |
| US-9592237-B2 | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2017-03-14 | — | — | US | disclosed |
| US-20160106752-A1 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2016-04-21 | — | — | US | disclosed |
| US-9238027-B2 | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2016-01-19 | — | — | US | disclosed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120142638-A1 | COMBINATION OF ORGANIC COMPOUNDS | WEBB RANDY LEE (US) | 2012-06-07 | — | — | US | disclosed |
| US-8143217-B2 | Use of DPP-IV inhibitor to reduce hypoglycemic events | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20120015945-A1 | USE OF CB1 ANTAGONISTS AND/OR INVERSE AGONISTS FOR THE PREPARATION OF DRUGS THAT INCREASE MOTOR NEURON EXCITABILITY | FUNDACION DEL HOSPITAL NACIONAL DE PA | 2012-01-19 | — | — | US | disclosed |
| WO-2007035665-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | NOVARTIS AG (CH) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007006790-A2 | COMBINATION OF A DPP-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| CN-1845735-A | Novel medical use of selective cb1-receptor antagonists | SOLVAY PHARM GMBH (DE) | 2006-10-11 | — | — | CN | disclosed |
| EP-1680116-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1663215-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1- RECEPTOR ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050101585-A1 | Use of selective CB1-antagonists in medical treatments | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| WO-2005039579-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005020992-A1 | NOVEL MEDICAL USE OF SELECTIVE CB1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142638-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, ACE, CNR2 | KDM4E 2798/4885RAB9A 320/4885NPC1 502/4885 |
| US-20160106752-A1 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability | CNR1, CNR2, CHRNA9 | KDM4E 2170/4885RAB9A 260/4885NPC1 2135/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | KDM4E 1177/4885RAB9A 3257/4885NPC1 893/4885 |
| US-20120015945-A1 | USE OF CB1 ANTAGONISTS AND/OR INVERSE AGONISTS FOR THE PREPARATION OF DRUGS THAT INCREASE MOTOR NEURON EXCITABILITY | CNR1, CNR2, CHRNA9 | KDM4E 2170/4885RAB9A 260/4885NPC1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.